南華生物(000504.SZ)控股子公司南華和平擬與藍衞通設立合資公司
格隆匯10月7日丨南華生物(000504.SZ)公佈,公司控股子公司南華和平醫院管理(湖南)有限公司(以下簡稱"南華和平")於2021年9月30日收到南華和平與北京藍衞通科技有限公司(以下簡稱"藍衞通")簽署的《關於設立博愛(北京)醫療科技有限公司(暫定名)之合作協議》(以下簡稱"合作協議"),雙方同意在北京市共同投資設立博愛(北京)醫療科技有限公司(暫定名,最終以工商部門核定為準,以下簡稱"博愛北京"或"合資公司",目前尚未完成設立),重點圍繞開展湖北、湖南、貴州等全國各省中國紅十字基金會(以下簡稱"紅基會")"博愛基層公衞援建計劃"。博愛北京的註冊資本暫定200萬元,其中南華和平出資102萬元,持股51%;藍衞通出資98萬元,持股49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.